AstraZeneca PLC Company Name:
AZN Stock Symbol:
NYSE Market:
News, Short Squeeze, Breakout and More Instantly...
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s ENHERTU reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease AstraZeneca and Daiichi Sankyo’s ENHERTU ® (fam-trastuzumab deruxtecan-...
MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy Global SAFFRON Phase III trial evaluating this combination is underway Preliminary results from the SAVANNAH Phase II trial showed that T...
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway — HONG KONG and SHANGHAI, China and FLORHA...